Sanofi India

Dividend stocks today: Here is the complete list of stocks to remain in focus during today's trading following their announcement of interim dividends.

Dividend stocks: Here's the complete list of stocks that will remain in focus next week, following their dividend announcements, along with key details

Emcure Pharma stock was quoting at ₹1,382.5, up 1.5 per cent from the previous day's close of ₹1,362.5 as the company announced a distribution and promotion partnership with Sanofi India

Emcure to distribute and promote Sanofi's oral anti-diabetic brands Amaryl and Cetapin in India, expanding access amid rising prevalence of uncontrolled diabetes

In the previous trading session, Sensex gained 182.34 points, or 0.22 per cent, to settle at 81,330.56 level. The Nifty50, meanwhile, closed 88.55 points, or 0.36 per cent higher at 24,666.90 level.

Sanofi India's Q4FY25 profit declined 12.5% Y-o-Y to ₹119.5 crore, while revenue rose 4.9%; operating profit improved 27% on better efficiency, says CFO

The ex-dividend date marks the day a stock begins trading without the right to receive the declared dividend, meaning investors must own the stock before this date to be eligible

The ex-dividend date marks the day a stock begins trading without the right to receive the declared dividend, meaning investors must own the stock before this date to be eligible

Technically, the term 'Death Cross' indicates a weak set-up as the stock's 50-day moving average has dropped below the long-term 200-day moving average.

Shares of CDSL last closed at Rs 1,382, up 0.25 per cent, valuing the company at Rs 28,879 crore

The fall in the share price came after the pharmaceutical company reported a weak set of June quarter of financial year 2025 (Q1FY25) results.

Each member of Sanofi India holding 1 equity share in Sanofi India as on the Record Date i.e. June 13, 2024 shall entitled to receive 1 equity share of Sanofi Consumer Healthcare India.

Shriram Finance announced that board has approved the sale of its housing finance subsidiary Shriram Housing Finance to Warburg Pincus for Rs 4,630 crore

Novavax said it would co-commercialize its Covid-19 vaccine with French drugmaker Sanofi and develop new Covid-19-influenza combination vaccines using Novavax's Matrix-M adjuvant

Sanofi reported that in India, over 100 million individuals are grappling with type 2 diabetes and its associated complexities

Aiming for a "fair share" in the Indian pharmaceutical market, French drug major Sanofi plans to introduce new drugs and enhance localisation while expanding the reach of its existing brands through collaboration with domestic drug firms, according to a top company official. The company plans to enhance its presence in the diabetes segment and grow its consumer healthcare business after spinning it off into a new entity while also looking at local production of its various best-in-class products in India. In an interaction with PTI, Sanofi India Managing Director Rodolfo Hrosz stated that the company has embarked on a mission to prepare for an accelerated growth path in the country. "We believe we're under-represented (in India) and we see a significant opportunity right now and in the future as well. The potential of this market is phenomenal," he said. He further said: "We are seeking the route to be better represented ... with a fair share of the Indian pharmaceutical ...

Under the terms of this agreement, Dr Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands, including Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri and Adacel

Open to licensing, collaboration in anti-diabetes space

Cipla will leverage its extensive network to distribute Sanofi's CNS portfolio, including Frisium, a leading anti-epileptic drug

Collaboration aligns with Sanofi's growth strategy in India, named 'India for India', aims to accelerate growth across its pharmaceuticals, specialty care, consumer healthcare, and vaccines business